<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39308551</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2452-199X</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bioactive materials</Title><ISOAbbreviation>Bioact Mater</ISOAbbreviation></Journal><ArticleTitle>Fc-empowered exosomes with superior epithelial layer transmission and lung distribution ability for pulmonary vaccination.</ArticleTitle><Pagination><StartPage>573</StartPage><EndPage>586</EndPage><MedlinePgn>573-586</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bioactmat.2024.08.015</ELocationID><Abstract><AbstractText>Mucosal vaccines offer potential benefits over parenteral vaccines for they can trigger both systemic immune protection and immune responses at the predominant sites of pathogen infection. However, the defense function of mucosal barrier remains a challenge for vaccines to overcome. Here, we show that surface modification of exosomes with the fragment crystallizable (Fc) part from IgG can deliver the receptor-binding domain (RBD) of SARS-CoV-2 to cross mucosal epithelial layer and permeate into peripheral lung through neonatal Fc receptor (FcRn) mediated transcytosis. The exosomes F-L-R-Exo are generated by genetically engineered dendritic cells, in which a fusion protein Fc-Lamp2b-RBD is expressed and anchored on the membrane. After intratracheally administration, F-L-R-Exo is able to induce a high level of RBD-specific IgG and IgA antibodies in the animals' lungs. Furthermore, potent Th1 immune-biased T cell responses were also observed in both systemic and mucosal immune responses. F-L-R-Exo can protect the mice from SARS-CoV-2 pseudovirus infection after a challenge. These findings hold great promise for the development of a novel respiratory mucosal vaccine approach.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences &amp; State Key Laboratory of Functions and Applications of Medicinal Plants &amp; Microbiology and Biochemical Pharmaceutical Engineering Research Center of Guizhou Provincial Department of Education, Guizhou Medical University, Guiyang, 550025, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Haonan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jingru</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yingqi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences &amp; State Key Laboratory of Functions and Applications of Medicinal Plants &amp; Microbiology and Biochemical Pharmaceutical Engineering Research Center of Guizhou Provincial Department of Education, Guizhou Medical University, Guiyang, 550025, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zehong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences &amp; State Key Laboratory of Functions and Applications of Medicinal Plants &amp; Microbiology and Biochemical Pharmaceutical Engineering Research Center of Guizhou Provincial Department of Education, Guizhou Medical University, Guiyang, 550025, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Xiran</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Zenglin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Advanced Research Institute of Multidisciplinary Science, School of Life Science, School of Medical Technology (Institute of Engineering Medicine), Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering Beijing Institute of Technology, Beijing, 100081, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Xiuli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences &amp; State Key Laboratory of Functions and Applications of Medicinal Plants &amp; Microbiology and Biochemical Pharmaceutical Engineering Research Center of Guizhou Provincial Department of Education, Guizhou Medical University, Guiyang, 550025, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Aiping</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100850, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Bioact Mater</MedlineTA><NlmUniqueID>101685294</NlmUniqueID><ISSNLinking>2452-199X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Exosomes</Keyword><Keyword MajorTopicYN="N">Fc</Keyword><Keyword MajorTopicYN="N">Mucosal immunity</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList><CoiStatement>A.Z. from the Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences. A patent application entitled "Recombinant plasmid Fc-Lamp2b-RBD and its preparation method and application thereof" was filed. All the other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39308551</ArticleId><ArticleId IdType="pmc">PMC11416621</ArticleId><ArticleId IdType="doi">10.1016/j.bioactmat.2024.08.015</ArticleId><ArticleId IdType="pii">S2452-199X(24)00353-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Miao G.G., Chen Z.Q., Cao H.S., Wu W.H., Chu X., Liu H.Y., Zhang L.Y., Zhu H.F., Cai H.Z., Lu X.L., Shi J.F., Liu Y., Feng T.T. From Immunogen to COVID-19 vaccines: prospects for the post-pandemic era. Biomed. Pharmacother. 2023;158</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9805901</ArticleId><ArticleId IdType="pubmed">36800265</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison H., Jackson S., McShane H. Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges. Front. Immunol. 2023;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10248465</ArticleId><ArticleId IdType="pubmed">37304270</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarim E.A., Inevi M.A., Ozkan I., Kecili S., Bilgi E., Baslar M.S., Ozcivici E., Karakus C.O., Tekin H.C. Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions. Biomed. Microdevices. 2023;25(2):10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10009869</ArticleId><ArticleId IdType="pubmed">36913137</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng N.N., Liu M.Z., Li W.T., Sun B.Y., Liu D.D., Wang G.Q., Shi J.W., Li L.S. Protein post-translational modification in SARS-CoV-2 and host interaction. Front. Immunol. 2023;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9880545</ArticleId><ArticleId IdType="pubmed">36713387</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus J.V., Wyka K., White T.M., Picchio C.A., Gostin L.O., Larson H.J., Rabin K., Ratzan S.C., Kamarulzaman A., El-Mohandes A. A survey of COVID-19 vaccine acceptance across 23 countries in 2022. Nat. Med. 2023;29:366–375.</Citation><ArticleIdList><ArticleId IdType="pubmed">36624316</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo C.Y., Lee W.H., Zhou Q.T. Recent advances in inhaled nanoformulations of vaccines and therapeutics targeting respiratory viral infections. Pharm Res-dordr. 2023;40(5):1015–1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10129308</ArticleId><ArticleId IdType="pubmed">37186073</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhakar P.K., Khurana N., Vyas M., Sharma V., Batiha G.E., Kaur H., Singh J., Kumar D., Sharma N., Kaushik A., Kumar R. Aspects of nanotechnology for COVID-19 vaccine development and its delivery applications. Pharmaceutics. 2023;15(2):451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9960567</ArticleId><ArticleId IdType="pubmed">36839773</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H.Q., Li H.Y., You H.L., Zhang P., Li N., Jiang N., Cao Y., Qin L., Qin G.X., Qu H.B., Wang H.Y., Zou B., He X., Li D., Zhao H.Z., Huang G., Li Y., Zhang H.F., Zhu L.P., Qiao H.M., Li H.J., Liu S.R., Gu L.N., Yin G.D., Hu Y., Xu S.B., Guo W.Y., Wang N.Y., Liu C.Y., Gao P.J., Cao J., Zheng Y., Zhang K.Y., Wang Y., Chen H., Zhang J., Mu D.M., Niu J.Q. Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China. Emerg. Microb. Infect. 2023;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9817129</ArticleId><ArticleId IdType="pubmed">36398721</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein C., Nassereldine H., Sorensen R.J.D., Amlag J., Bisignano C., Byrne S., Castro E., Coberly K., Collins J.K., Dalos J., Daoud F., Deen A., Gakidou E., Giles J.R., Hulland E.N., Huntley B.M., Kinzel K.E., Lozano R., Mokdad A.H., Pham T., Pigott D.M., Reiner R.C., Vos T., Hay S.I., Murray C.J.L., Lim S.S. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023;401(10379):833–842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9998097</ArticleId><ArticleId IdType="pubmed">36930674</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Cui K., Costabel U., Zhang X. Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic. Explorations. 2022;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349967</ArticleId><ArticleId IdType="pubmed">35941992</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng C., Tan P., Nie G., Zhu M. Biomimetic and bioinspired nano‐platforms for cancer vaccine development. Explorations. 2023;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10624393</ArticleId><ArticleId IdType="pubmed">37933383</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X.Y., Xia Y.T., Liu X.F., Xu Y.L., Lu P.Y., Dong Z.P., Liu J., Liang G.F. A perspective on SARS-CoV-2 virus-like particles vaccines. Int. Immunopharm. 2023;115</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832101</ArticleId><ArticleId IdType="pubmed">36649673</ArticleId></ArticleIdList></Reference><Reference><Citation>Ul Haq I., Krukiewicz K., Yahya G., Ul Haq M., Maryam S., Mosbah R.A., Saber S., Alrouji M. The breadth of bacteriophages contributing to the development of the phage-based vaccines for COVID-19: an ideal platform to design the multiplex vaccine. J. Mol. Sci. 2023;24(2):1536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9861788</ArticleId><ArticleId IdType="pubmed">36675046</ArticleId></ArticleIdList></Reference><Reference><Citation>Das R., Hyer R.N., Burton P., Miller J.M., Kuter B.J. Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape. Hum. Vaccines Immunother. 2023;19(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9980456</ArticleId><ArticleId IdType="pubmed">36629006</ArticleId></ArticleIdList></Reference><Reference><Citation>Popowski K.D., Blanca López de Juan Abad, George A., Silkstone D., Belcher E., Chung J. Inhalable exosomes outperform liposomes as mrna and protein drug carriers to the lung. Extracellular vesicle. 2022;1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9213043</ArticleId><ArticleId IdType="pubmed">36523538</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui Y., Li J., Qu J.Q., Fang T., Zhang H.Y., Zhang J., Wang Z.R., Xia M.Y., Dai Y.H., Wang D.K. Dual-responsive nanovaccine for cytosolic delivery of antigens to boost cellular immune responses and cancer immunotherapy. Asian J. Pharm. Sci. 2022;17(4):583–595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9459061</ArticleId><ArticleId IdType="pubmed">36101894</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziqi W., Kai C., Costabel U., Xiaoju Z.J.E. Nanotechnology-facilitated vaccine development during the coronavirus disease 2019 (COVID-19) pandemic. Explorations. 2022;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349967</ArticleId><ArticleId IdType="pubmed">35941992</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayrhofer P., Hunjadi M., Kunert R. Functional trimeric SARS-CoV-2 envelope protein expressed in stable CHO cells. Front. Bioeng. Biotechnol. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8718689</ArticleId><ArticleId IdType="pubmed">34976974</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2021;183(6):1735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833104</ArticleId><ArticleId IdType="pubmed">33306958</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J.Y., Collins N.D., Mercado N.B., McMahan K., Chandrashekar A., Liu J.Y., Anioke T., Chang A.Q., Giffin V.M., Hope D.L., Sellers D., Nampanya F., Gardner S., Barrett J., Wan H.H., Velasco J., Teow E., Cook A., Ry A.V., Pessaint L., Andersen H., Lewis M.G., Hofer C., Burke D.S., Barkei E.K., King H.A.D., Subra C., Bolton D., Modjarrad K., Michael N.L., Barouch D.H. Protective efficacy of gastrointestinal SARS-CoV-2 delivery against intranasal and intratracheal SARS-CoV-2 challenge in rhesus macaques. J. Virol. 2022;96(2):e0159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8791250</ArticleId><ArticleId IdType="pubmed">34705557</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravichandran S., Grubbs G., Tang J.J., Lee Y., Huang C., Golding H., Khurana S. Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2-infected individuals reveal unlinked immune signatures. Sci. Adv. 2021;7(42)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8514093</ArticleId><ArticleId IdType="pubmed">34644111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejemel M., Li Q., Hou S.R., Schiller Z.A., Tree J.A., Wallace A., Amcheslavsky A., Yilmaz N.K., Buttigieg K.R., Elmore M.J., Godwin K., Coombes N., Toomey J.R., Schneider R., Ramchetty A.S., Close B.J., Chen D.Y., Conway H.L., Saeed M., Ganesa C., Carroll M.W., Cavacini L.A., Klempner M.S., Schiffer C.A., Wang Y. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nat Commum. 2020;11(1):4198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442812</ArticleId><ArticleId IdType="pubmed">32826914</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingstad-Bakke B., Lee W., Chandrasekar S.S., Gasper D.J., Salas-Quinchucua C., Cleven T., Sullivan J.A., Talaat A., Osorio J.E., Suresh M. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. P Natl Acad Sci. USA. 2022;119</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9171754</ArticleId><ArticleId IdType="pubmed">35561224</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng F.L., Wen Z.Y., Chen J.S., Yuan Y., Wang C.C., Sun C.J. Strategies to develop a mucosa-targeting vaccine against emerging infectious diseases. Viruses-Basel. 2022;14(3):520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8952777</ArticleId><ArticleId IdType="pubmed">35336927</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan A.O., Kafai N.M., Dmitriev I.P., Fox J.M., Smith B.K., Harvey I.B., Chen R.E., Winkler E.S., Wessel A.W., Case J.B., Kashentseva E., McCune B.T., Bailey A.L., Zhao H.Y., VanBlargan L.A., Dai Y.N., Ma M.S., Adams L.J., Shrihari S., Danis J.E., Gralinski L.E., Hou Y.J., Schafer A., Kim A.S., Keeler S.P., Weiskopf D., Baric R.S., Holtzman M.J., Fremont D.H., Curiel D.T., Diamond M.S. A single-dose intranasal Chad vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. 2020;183(1):169–184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437481</ArticleId><ArticleId IdType="pubmed">32931734</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao L.C., Yu W.L., Shen L.J., Yan W.Y., Qi J.M., Hu T. Mucosal SARS-CoV-2 nanoparticle vaccine based on mucosal adjuvants and its immune effectiveness by intranasal administration. Acs Appl Mater Inter. 2023;15(30):35895–35905.</Citation><ArticleIdList><ArticleId IdType="pubmed">37466148</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakhra K., Abraham W., Wang C.S., Moynihan K.D., Li N., Donahue N., Baldeon A.D., Irvine D.J. Exploiting albumin as a mucosal vaccine chaperone for robust generation of lung-resident memory T cells. Sci. Immunol. 2021;6(57)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8279396</ArticleId><ArticleId IdType="pubmed">33741657</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y.F., Pi J., Xu J.F. Emerging role of exosomes in tuberculosis: from immunity regulations to vaccine and immunotherapy. Front. Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8047325</ArticleId><ArticleId IdType="pubmed">33868247</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle L.M., Wang M.Z. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells-Basel. 2019;8(7):72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6678302</ArticleId><ArticleId IdType="pubmed">31311206</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenbergh M.F.S., Stoorvogel W. Antigen presentation by extracellular vesicles from professional antigen-presenting cells. Annu. Rev. Immunol. 2018;36:435–459.</Citation><ArticleIdList><ArticleId IdType="pubmed">29400984</ArticleId></ArticleIdList></Reference><Reference><Citation>Macia L., Nanan R., Hosseini-Beheshti E., Grau G.E. Host- and microbiota-derived extracellular vesicles, immune function, and disease development. Int. J. Mol. Sci. 2020;21(1):107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6982009</ArticleId><ArticleId IdType="pubmed">31877909</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevaskis N., Kaminskas L., Porter C. From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. Nat. Rev. Drug Discov. 2015;14(11):781–803.</Citation><ArticleIdList><ArticleId IdType="pubmed">26471369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurywchak P., Tavormina J., Kalluri R. The emerging roles of exosomes in the modulation of immune responses in cancer. Genome Med. 2018;10:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5868069</ArticleId><ArticleId IdType="pubmed">29580275</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel M., Gabrielsson S. Personalized medicine and back-allogeneic exosomes for cancer immunotherapy. J. Intern. Med. 2021;289(2):138–146.</Citation><ArticleIdList><ArticleId IdType="pubmed">31359504</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Li F., Ye T., Wang J.H., Lyu C.L., Qing S., Ding Z.W., Gao X.Y., Jia R.R., Yu D., Ren J., Wei W., Ma G.H. Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor microenvironment. Sci. Transl. Med. 2021;13</Citation><ArticleIdList><ArticleId IdType="pubmed">34644149</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahan S., Mukherjee S., Ali S., Bhardwaj U., Choudhary R.K., Balakrishnan S., Naseem A., Mir S.A., Banawas S., Alaidarous M., Alyenbaawi H., Iqbal D., Siddiqui A.J. Pioneer role of extracellular vesicles as modulators of cancer initiation in progression, drug therapy, and vaccine prospects. Cells-Basel. 2022;11(3):490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8833976</ArticleId><ArticleId IdType="pubmed">35159299</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabrice Andre, Nathalie, et al. Exosomes as potent cell-free peptide-based vaccine.I."Exosomes as potent cell-free peptide-based vaccine.I.dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells". J. Immunol. 2004;172(4):2126–2136.</Citation><ArticleIdList><ArticleId IdType="pubmed">14764678</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z.Z., Popowski K.D., Zhu D.S., Abad B.L.D., Wang X.Y., Liu M.R., Lutz H., De Naeyer N., DeMarco C.T., Denny T.N., Dinh P.U.C., Li Z.H., Cheng K. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat. Biomed. Eng. 2022;6(7):791–805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10782831</ArticleId><ArticleId IdType="pubmed">35788687</ArticleId></ArticleIdList></Reference><Reference><Citation>Popowski K.D., Moatti A., Scull G., Silkstone D., Lutz H., Abad B.L.D., George A., Belcher E., Zhu D.S., Mei X., Cheng X., Cislo M., Ghodsi A., Cai Y.H., Huang K., Li J.L., Brown A.C., Greenbaum A., Dinh P.U.C., Cheng K. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter. 2022;5(9):2960–2974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9272513</ArticleId><ArticleId IdType="pubmed">35847197</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W.T., Yang G.L., Wang Q., Huang H.B., Jiang Y.L., Shi C.W., Wang J.Z., Huang K.Y., Jin Y.B., Wang C.F. Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum. Antivir. Res. 2017;138:9–21.</Citation><ArticleIdList><ArticleId IdType="pubmed">27908830</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z.L., Zhou X.Y., Gao X.T., Bai D.N., Dong Y., Sun W.Q., Zhao L.B., Wei M.Y., Yang X.K., Yang G.D., Yuan L.J. Fusion protein engineered exosomes for targeted degradation of specific RNAs in lysosomes: a proof-of-concept study. J. Extracell. Vesicles. 2020;9(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7580726</ArticleId><ArticleId IdType="pubmed">33133429</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederer K., Castano D., Atria D.G., Oguin T.H., Wang S., Manzoni T.B., Muramatsu H., Hogan M.J., Amanat F., Cherubin P., Lundgreen K.A., Tam Y.K., Fan S.H.Y., Eisenlohr L.C., Maillard I., Weissman D., Bates P., Krammer F., Sempowski G.D., Pardi N., Locci M. SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation. Immunity. 2020;53(6):1281–1295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7680029</ArticleId><ArticleId IdType="pubmed">33296685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni J., Witzigmann D., Chen S., Cullis P., van der Meel R. Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Accounts Chem. Res. 2019;52(9):2435–2444.</Citation><ArticleIdList><ArticleId IdType="pubmed">31397996</ArticleId></ArticleIdList></Reference><Reference><Citation>Vllasaliu D., Alexander C., Garnett M., Eaton M., Stolnik S. Fc-mediated transport of nanoparticles across airway epithelial cell layers. J. Contr. Release. 2012;158(3):479–486.</Citation><ArticleIdList><ArticleId IdType="pubmed">22200577</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo D., Yang X., Li T., Ning N., Jin S., Shi Z., Gu H., Li D., Gao Y., Wang H. An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants. Signal Transduct. Tar. 2022;7(1):327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9482636</ArticleId><ArticleId IdType="pubmed">36115830</ArticleId></ArticleIdList></Reference><Reference><Citation>Nizard M., Roussel H., Diniz M.O., Karaki S., Tran T., Voron T., Dransart E., Sandoval F., Riquet M., Rance B., Marcheteau E., Fabre E., Mandavit M., Terme M., Blanc C., Escudie J.B., Gibault L., Le Pimpec Barthes F., Granier C., Ferreira L.C.S., Badoual C., Johannes L., Tartour E. Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat. Commun. 2017;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5458068</ArticleId><ArticleId IdType="pubmed">28537262</ArticleId></ArticleIdList></Reference><Reference><Citation>Stapleton N., Einarsdóttir H., Stemerding A., Vidarsson G.J. I.r. The multiple facets of FcRn in immunity. Immunol. Rev. 2015;268(1):253–268.</Citation><ArticleIdList><ArticleId IdType="pubmed">26497526</ArticleId></ArticleIdList></Reference><Reference><Citation>Castaneda D., Dhommée C., Baranek T., Dalloneau E., Lajoie L., Valayer A., Arnoult C., Demattéi M., Fouquenet D., Parent C., Heuzé-Vourc'h N., Gouilleux-Gruart V.J. F.i. i. Lack of FcRn impairs natural killer cell development and functions in the tumor microenvironment. Front. Immunol. 2018;9:2259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6172308</ArticleId><ArticleId IdType="pubmed">30323819</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma V., Mukhopadhyay C.D. Exosome as drug delivery system: current advancements. Extracellular Vesicle. 2024;3</Citation></Reference><Reference><Citation>Pitt J.M., Fabrice André, Amigorena S., Soria J.C., Zitvogel L. Dendritic cell–derived exosomes for cancer therapy. J. Clin. Invest. 2016;126(4):1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4811123</ArticleId><ArticleId IdType="pubmed">27035813</ArticleId></ArticleIdList></Reference><Reference><Citation>Xinyu Y., Jiale C., Ning W., et al. Clinical use of dendritic cell-derived exosomes for hepatocellular carcinoma immunotherapy: how far we are? J. Hepatol. 2018;69:984–986.</Citation><ArticleIdList><ArticleId IdType="pubmed">30093161</ArticleId></ArticleIdList></Reference><Reference><Citation>Heida R., Hinrichs W., Frijlink H. Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19, Expert. Rev. Vaccines. 2021;21(7):957–974.</Citation><ArticleIdList><ArticleId IdType="pubmed">33749491</ArticleId></ArticleIdList></Reference><Reference><Citation>T. Mao, B. Israelow, M. Peña-Hernández, A. Suberi, L. Zhou, S. Luyten, M. Reschke, H. Dong, R. Homer, W. Saltzman, A. J. S. Iwasaki, Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses, Science. 378 (6622), eabo2523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9798903</ArticleId><ArticleId IdType="pubmed">36302057</ArticleId></ArticleIdList></Reference><Reference><Citation>O. Alfi, A. Yakirevitch, O. Wald, O. Wandel, U. Izhar, E. Oiknine-Djian, Y. Nevo, S. Elgavish, E. Dagan, O. Madgar, G. Feinmesser, E. Pikarsky, M. Bronstein, O. Vorontsov, W. Jonas, J. Ives, J. Walter, Z. Zakay-Rones, M. Oberbaum, A. Panet, D. G. Wolf, J. Virol. 95 (14), e00130-21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8223920</ArticleId><ArticleId IdType="pubmed">33893170</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Popowski K., Zhu D., de Juan Abad B., Wang X., Liu M., Lutz H., De Naeyer N., DeMarco C., Denny T., Dinh P., Li Z., Cheng K.J. N.b. e. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat. Biomed. Eng. 2022;6(7):791–805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10782831</ArticleId><ArticleId IdType="pubmed">35788687</ArticleId></ArticleIdList></Reference><Reference><Citation>Charoenviriyakul C., Takahashi Y., Nishikawa M., Takakura Y. Preservation of exosomes at room temperature using lyophilization. Int. J. Pharm. (Amst.) 2018;553(1–2):1–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30316791</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>